Medical Devices Europe

Europe Neuromodulation for Depression Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Europe Neuromodulation for Depression Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $275.3 Mn Placeholder estimate
Estimate 2025 $298.1 Mn 19% of the global market
Projected 2034 $611.1 Mn 105% Adds $312.9 Mn over 9 forecast years
CAGR 2025–2034 8.3% Faster than 57% of 173 Medical Devices markets here
Key players 5
  • Europe is 18.95% of the global market.
  • Among regions, the largest is North America at $807.4 Mn.
  • Fastest growing: Africa at 11.4% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$312.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Neuromodulation for Depression Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $275.3 Mn — —
2025 (base) $298.1 Mn +$22.8 Mn —
2026 (forecast) $322.9 Mn +$24.7 Mn +8.3%
2027 (forecast) $349.7 Mn +$26.8 Mn +17.3%
2028 (forecast) $378.7 Mn +$29.0 Mn +27%
2029 (forecast) $410.2 Mn +$31.4 Mn +37.6%
2030 (forecast) $444.2 Mn +$34.0 Mn +49%
2031 (forecast) $481.1 Mn +$36.9 Mn +61.4%
2032 (forecast) $521.0 Mn +$39.9 Mn +74.7%
2033 (forecast) $564.2 Mn +$43.2 Mn +89.2%
2034 (forecast) $611.1 Mn +$46.8 Mn +105%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Neuromodulation for Depression Market Analysis at a glance
Market size, 2025$298.1 Mn placeholder estimate
Forecast, 2034$611.1 Mn placeholder estimate
Growth (CAGR), 2025–20348.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, setting and end user (see all)
Key playersNeuronetics, BrainsWay, Magstim, LivaNova PLC, Flow Neuroscience (see all)
Regulator in EuropeEU MDRSource: European Commission, medical devices. Checked 14 Nov 2026.
Active clinical trials63 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Neuromodulation for Depression Market Analysis Executive Summary

Neuromodulation for depression uses magnetic or electrical stimulation of the brain, such as TMS, to treat depression that does not respond to medicines.

Key segments of the neuromodulation for Depression market include technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy and Vagus Nerve Stimulation) and setting (Clinics, Hospitals and Home).

Bar chart: Europe Neuromodulation for Depression market size, 2024–2034, placeholder estimates. $275.3 Mn in 2024, $298.1 Mn in 2025 and $611.1 Mn in 2034, 8.3% CAGR.
Europe Neuromodulation for Depression market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Neuromodulation for Depression Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the neuromodulation for Depression market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the neuromodulation for Depression market.

Competitive Landscape for Neuromodulation for Depression Market in Europe

The neuromodulation for Depression market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Neuromodulation for Depression Market in Europe

Neuromodulation for Depression in Europe: rules, payment and research

In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.⁠[1] In the countries we cover here, medical devices are regulated by ANSM (France)⁠[2], BfArM (Germany)⁠[3], Ministry of Health (Italy)⁠[4], Roszdravnadzor (Russia)⁠[5], AEMPS (Spain)⁠[6] and MHRA (UK)⁠[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[8] ClinicalTrials.gov lists 63 studies on Neuromodulation for Depression that are recruiting, active or about to start in Europe.⁠[9]

[1] European Commission, medical devices. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Ministry of Health. Checked 14 Nov 2026.

[5] Roszdravnadzor. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] European Commission, health technology assessment. Checked 14 Nov 2026.

[9] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neuromodulation for Depression products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Neuromodulation for Depression right now, from free public sources.

Clinical trials

63 active trials in UK, Germany, France, Italy, Spain and Russia

Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.

Top trial sponsors (worldwide)

  1. Magnetic Tides 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Neuromodulation for Depression in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Neuromodulation for Depression market in Europe?
Placeholder estimate: about $298.1 Mn in 2025, rising to about $611.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neuromodulation for Depression market in Europe growing?
Placeholder estimate: about 8.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neuromodulation for Depression market report cover?
The report splits the market by technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy, Vagus Nerve Stimulation, tDCS), setting (Clinics, Hospitals, Home) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Neuromodulation for Depression market?
Key players include Neuronetics, BrainsWay, Magstim, LivaNova PLC and Flow Neuroscience.
What is driving the Neuromodulation for Depression market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
Who regulates Neuromodulation for Depression in Europe?
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first. Source: European Commission, medical devices. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Neuromodulation for Depression are running in Europe?
63 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Neuromodulation for Depression?
PubMed lists 74 papers on Neuromodulation for Depression added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Europe

See all

Related on mental health and brain and nerves

See the topic